バイオアッセイサービス市場：治療タイプ別（細胞治療、遺伝子治療）、治療領域別（腫瘍性疾患、感染症、自己免疫疾患、希少/遺伝性疾患、心血管疾患、代謝性疾患、血液疾患、神経疾患、眼科疾患、その他治療領域）、事業規模別（探索、前臨床、臨床）、地域別（北米、欧州、アジア太平洋地域、中南米、中東・アフリカ、その他地域）：業界動向と世界予測、2021-2035年

Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders, Blood Disorders, Neurological Disorders, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

細胞治療と遺伝子治療のバイオアッセイサービス市場は、2021年に1億5500万ドルに達すると予測され、予測期間2021-2032年のCAGRは30.1%で成長すると予測されている。重篤な病状に対処するために細胞療法と遺伝... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Roots Analysis ルーツアナリシス	2023年7月1日	US$4,799 シングルユーザライセンスライセンス・価格情報注文方法はこちら	310	英語

サマリー

細胞治療と遺伝子治療のバイオアッセイサービス市場は、2021年に1億5500万ドルに達すると予測され、予測期間2021-2032年のCAGRは30.1%で成長すると予測されている。

重篤な病状に対処するために細胞療法と遺伝子療法が好まれるようになったことで、さまざまな疾患の治療に対する開発と承認が大幅に増加した。現在、30以上の治療法が承認されており、1,200以上の治療法がさまざまな開発段階にある。このような好感度の上昇により、これらの先進的な治療法は、バイオ医薬品業界において高く評価される分野となる可能性を秘めている。
その可能性にもかかわらず、細胞治療や遺伝子治療の開発は複雑で、経済的にも厳しい。その結果、アウトソーシングが好まれるようになり、企業は製品開発と製造のさまざまな側面を処理する専門サービス・プロバイダーに大きく依存している。バイオ医薬品企業の大半はアウトソーシングを好んでおり、その支出のかなりの部分がこれらのサービスに向けられている。環境試験、生物分析試験、化学試験、安定性試験、試験法開発、バリデーション、製品特性評価など、さまざまな種類の試験を含む分析試験サービスは、顕著な需要の急増が見られる。
このような分析試験サービスのアウトソーシング需要の増加により、細胞治療や遺伝子治療のためのテーラーメイド・バイオアッセイ・サービスの提供に重点を置く専門的な受託研究機関が出現した。これらの機関は高度な技術と専門知識を有しており、試験の最適化、コスト効率、期間の短縮に役立っている。提供サービスの強化に向けた継続的な取り組みにより、細胞・遺伝子治療バイオアッセイサービス市場は予測期間中に一貫して成長すると予想される。

レポート対象範囲
 企業詳細（設立年、規模、本社、施設）、提供サービス（in vitro、in vivo）、バイオアッセイの種類、提供サービス（イムノアッセイ、PCR、フローサイトメトリーなど）、アプリケーション（細胞治療、遺伝子治療）など、世界の細胞・遺伝子治療バイオ分析検査サービス市場の詳細な概要。
 世界のバイオアッセイサービスプロバイダーの競合分析。サービス力、適用性、サプライヤーの経験を考慮。
 細胞療法と遺伝子治療のバイオアッセイサービスを提供する北米、欧州、アジア太平洋地域の主要企業のプロフィール。会社概要、サービスポートフォリオ、提供品目、バイオアッセイの種類、施設、最近の動向、将来の展望を網羅。
 提供サービスや応用分野に基づく細胞・遺伝子治療サービスプロバイダーの市場動向分析。バイオ分析施設の所在地を示す地図付き。
 サービスの種類、応用分野、戦略的イニシアチブに焦点を当てた、サービスプロバイダーが参加する世界的イベントの分析。
 開発段階別、治療分野別、開発者タイプ別の分布を含む、細胞・遺伝子治療市場展望のケーススタディ。
 バイオアッセイサービスプロバイダーとの提携が予想される細胞治療開発企業260社と遺伝子治療開発企業190社を、企業力、パイプラインの成熟度、能力に基づいて詳細に分析。

主要市場企業
 CCRM
 ネクセリス
 パシフィックバイオラボ
 PPDラボラトリーズ
 WuXi Advanced Therapies
 アナバイオテック
 インターテックファーマシューティカルサービス
 ロンザ
 ポルトン・バイオ

ページTOPに戻る

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
2.1. Chapter Overview
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Bioassays
3.3. Cell and Gene Therapy Bioassays
3.4. Importance of Bioassays in Cell and Gene Therapy
3.5. Challenges Related to Cell and Gene Therapy Bioassays
3.6. Role of Contract Service Providers and Prevalent Outsourcing Trends
3.7. Future Perspectives

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell and Gene Therapy Bioassay Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Location of Bioanalytical Facilities
4.2.6. Analysis by Type of Bioassay(s) Offered
4.2.7. Analysis by Types of Offering(s) of Bioassay
4.2.8. Analysis of Type of Bioanalytical Service(s) Offered
4.2.9. Analysis by Application Area
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in North America
5.5. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in Europe and Asia-Pacific
6. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. CCRM
6.2.1. Company Overview
6.2.2. Cell and Gene Therapy Bioassay Service Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Nexelis
6.3.1. Company Overview
6.3.2. Cell and Gene Therapy Bioassay Service Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Pacific BioLabs
6.4.1. Company Overview
6.4.2. Cell and Gene Therapy Bioassay Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. PPD Laboratories
6.5.1. Company Overview
6.5.2. Cell and Gene Therapy Bioassay Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. WuXi Advanced Therapies
6.6.1. Company Overview
6.6.2. Cell and Gene Therapy Bioassay Service Portfolio
6.6.3. Recent Developments and Future Outlook
7. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. AnaBioTec
7.2.1. Company Overview
7.2.2. Cell and Gene Therapy Bioassay Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Intertek Pharmaceutical Services
7.3.1. Company Overview
7.3.2. Cell and Gene Therapy Bioassay Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. Lonza
7.4.1. Company Overview
7.4.2. Cell and Gene Therapy Bioassay Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Porton Bio
7.5.1. Company Overview
7.5.2. Cell and Gene Therapy Bioassay Service Portfolio
7.5.3. Recent Developments and Future Outlook
8. MARKET TREND ANALYSIS
8.1. Chapter Overview
8.2 Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioanalytical Service(s) Offered and Application Area
8.3. Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
8.4 Cell and Gene Therapy Bioassay Service Providers: Analysis by Location of Bioanalytical facilities
8.4.1. Players with Bioanalytical Facilities in US
8.4.2. Players with Bioanalytical Facilities in Rest of the World
9. GLOBAL EVENT AND STRATEGIC INITIATIVE ANALYSIS
9.1. Chapter Overview
9.2. Cell and Gene Therapy Bioassay Service Providers: List of Event and Strategic Initiatives
9.2.1. Analysis by Year of Event
9.2.2. Analysis by Type of Event
9.2.3. Analysis by Year and Type of Event
9.2.4. Analysis by Type of Services Involved
9.2.5. Analysis by Application Area
9.2.6. Prominent Players: Analysis by Number of Events and Strategic Initiatives
10. CASE STUDY: MARKET LANDSCAPE OF CELL AND GENE THERAPIES
10.1. Chapter Overview
10.2. Cell Therapy Market
10.2.1. T-Cell Immunotherapies: Development Pipeline
10.2.1.1. Analysis by Type of Product
10.2.2. CAR-T Cell Therapies: Development Pipeline
10.2.2.1. Analysis by Phase of Development
10.2.2.2. Analysis by Therapeutic Area
10.2.2.3. Analysis by Type of Developer
10.2.2.4. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development
10.2.3. TCR-based Therapies: Development Pipeline
10.2.3.1. Analysis by Phase of Development
10.2.3.2. Analysis by Therapeutic Area
10.2.3.3. Analysis by Type of Developer
10.2.3.4. Key Industry Players: Analysis by Number of TCR-based Therapies in Development
10.2.4. TIL-based Therapies: Development Pipeline
10.2.4.1. Analysis by Phase of Development
10.2.4.2. Analysis by Therapeutic Area
10.2.4.3. Analysis by Type of Developer
10.2.4.4. Key Industry Players: Analysis by Number of TIL-based Therapies in Development
10.3. Gene Therapy Market
10.3.1. Gene Therapy Market: Clinical and Commercial Pipeline
10.3.1.1. Analysis by Phase of Development
10.3.1.2. Analysis by Therapeutic Area
10.3.2. Gene Therapy Market: Development Pipeline
10.3.2.1. Analysis by Phase of Development
10.3.2.2. Analysis by Therapeutic Area
11. LIKELY PARTNERS FOR CELL THERAPY BIOASSAY SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Potential Strategic Partners for Cell Therapy Bioassay Service Providers
11.3.1. Likely Partner Opportunities for Stem Cell Therapy Bioassay Service Providers
11.3.2. Likely Partner Opportunities for CAR-T Therapy Bioassay Service Providers
11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy Bioassay Service Providers
11.3.4. Likely Partner Opportunities for Tumor Cell Therapy Bioassay Service Providers
11.3.5. Likely Partner Opportunities for NK Cell Therapy Bioassay Service Providers
12. LIKELY PARTNERS FOR GENE THERAPY BIOASSAY SERVICE PROVIDERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Potential Strategic Partners for Gene Therapy Bioassay Service Providers
12.3.1. Likely Partner Opportunities in North America
12.3.2. Likely Partner Opportunities in Europe
12.3.3. Likely Partner Opportunities in Asia-Pacific
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Cell and Gene Therapy Bioassay Services Market
13.3.1. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Therapy
13.3.2. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Therapeutic Area
13.3.3. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Scale of Operation
13.3.4. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Geography
13.4. Cell Therapy Bioassay Services Market in North America, 2021-2035
13.4.1. Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2035
13.4.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2035
13.4.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2035
13.4.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2035
13.4.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2035
13.4.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2035
13.4.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2035
13.4.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2035
13.4.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2035
13.4.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2035
13.4.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2035
13.4.2. Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2035
13.4.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2035
13.4.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2035
13.4.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2035
13.5. Cell Therapy Bioassay Services Market in Europe, 2021-2035
13.5.1. Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2035
13.5.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2035
13.5.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2035
13.5.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2035
13.5.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2035
13.5.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2035
13.5.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2035
13.5.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2035
13.5.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2035
13.5.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2035
13.5.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2035
13.5.2. Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2035
13.5.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2035
13.5.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2035
13.5.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2035
13.6. Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2035
13.6.1. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2035
13.6.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2035
13.6.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2035
13.6.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2035
13.6.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2035
13.6.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2035
13.6.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2035
13.6.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2035
13.6.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2035
13.6.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2035
13.6.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2035
13.6.2. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2035
13.6.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2035
13.6.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2035
13.6.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2035
13.7. Cell Therapy Bioassay Services Market in Latin America, 2021-2035
13.7.1. Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2035
13.7.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2035
13.7.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2035
13.7.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2035
13.7.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2035
13.7.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2035
13.7.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2035
13.7.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2035
13.7.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2035
13.7.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2035
13.7.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2035
13.7.2. Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2035
13.7.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2035
13.7.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2035
13.7.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2035
13.8. Cell Therapy Bioassay Services Market in MENA, 2021-2035
13.8.1. Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2035
13.8.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2035
13.8.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2035
13.8.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2035
13.8.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2035
13.8.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2035
13.8.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2035
13.8.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2035
13.8.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2035
13.8.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2035
13.8.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2035
13.8.2. Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2035
13.8.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2035
13.8.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2035
13.8.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2035
13.9. Gene Therapy Bioassay Services Market in North America, 2021-2035
13.9.1. Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2035
13.9.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2035
13.9.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2035
13.9.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2035
13.9.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2035
13.9.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2035
13.9.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2035
13.9.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2035
13.9.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2035
13.9.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2035
13.9.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2035
13.9.2. Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2035
13.9.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2035
13.9.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2035
13.9.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2035
13.10. Gene Therapy Bioassay Services Market in Europe, 2021-2035
13.10.1. Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2035
13.10.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2035
13.10.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2035
13.10.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2035
13.10.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2035
13.10.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2035
13.10.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2035
13.10.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2035
13.10.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2035
13.10.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2035
13.10.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2035
13.10.2. Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2035
13.10.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2035
13.10.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2035
13.10.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2035
13.11. Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2035
13.11.1. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2035
13.11.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2035
13.11.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2035
13.11.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2035
13.11.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2035
13.11.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2035
13.11.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2035
13.11.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2035
13.11.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2035
13.11.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2035
13.11.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2035
13.11.2. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2035
13.11.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2035
13.11.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2035
13.11.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2035
13.12. Gene Therapy Bioassay Services Market in Latin America, 2021-2035
13.12.1. Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2035
13.12.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2035
13.12.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2035
13.12.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2035
13.12.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2035
13.12.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2035
13.12.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2035
13.12.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2035
13.12.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2035
13.12.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2035
13.12.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2035
13.12.2. Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2035
13.12.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2035
13.12.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2035
13.12.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2035
13.13. Gene Therapy Bioassay Services Market in MENA, 2021-2035
13.13.1. Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2035
13.13.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2035
13.13.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2035
13.13.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2035
13.13.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2035
13.13.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2035
13.13.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2035
13.13.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2035
13.13.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2035
13.13.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2035
13.13.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2035
13.13.2. Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2035
13.13.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2035
13.13.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2035
13.13.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2035
14. CONCLUSION
14.1. Chapter Overview
15. EXECUTIVE INSIGHTS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

ページTOPに戻る

Table of Contents

Summary

The bioassay services market for cell therapy and gene therapy is expected to reach USD 155 million in 2021 anticipated to grow at a CAGR of 30.1% during the forecast period 2021-2032

The preference for cell and gene therapies in addressing severe medical conditions has led to a significant increase in their development and approval for treating various diseases. Currently, more than 30 therapies have been approved, with over 1,200 in different stages of development. This rise in favorability positions these advanced therapies to potentially become a highly esteemed segment in the biopharmaceutical industry.
Despite their potential, developing cell and gene therapies is complex and financially demanding. Consequently, outsourcing has become a favored approach, with companies relying heavily on specialized service providers to handle different aspects of their product development and manufacturing. The majority of biopharmaceutical companies prefer outsourcing, with a significant portion of their spending directed towards these services. Analytical testing services, including various types of testing like environmental, bioanalytical, chemistry, stability testing, method development, validation, and product characterization, have seen a notable surge in demand.
This increased demand for outsourcing analytical testing services has led to the emergence of specialized contract research organizations focusing on offering tailored bioassay services for cell and gene therapies. These organizations possess advanced technology and expertise, aiding in study optimization, cost efficiency, and timeline reduction. With ongoing efforts to enhance their offerings, the market for cell and gene therapy bioassay services is expected to consistently grow in the forecasted period.

Report Coverage
 Detailed overview of the global cell & gene therapy bioanalytical testing services market, including company details (year of establishment, size, HQ, facilities), offerings (in vitro, in vivo), bioassay types, services offered (immunoassay, PCR, flow cytometry, etc.), and applications (cell therapy, gene therapy).
 Competitive analysis of bioassay service providers globally, considering service strength, applicability, and supplier experience.
 Profiles of key players in North America, Europe, and Asia-Pacific offering cell and gene therapy bioassay services, covering company overview, service portfolio, offerings, bioassay types, facilities, recent developments, and future outlook.
 Market trend analysis of cell and gene therapy service providers based on offered services and application areas, with a map showing bioanalytical facility locations.
 Analysis of global events attended by service providers, focusing on service types, application areas, and strategic initiatives.
 Case study of the cell and gene therapy market landscape, including distribution by development phase, therapeutic areas, and developer types.
 In-depth analyses of 260 cell therapy developers and 190 gene therapy developers anticipated to partner with bioassay service providers, based on company strength, pipeline maturity, and capabilities.

Key Market Companies
 CCRM
 Nexelis
 Pacific BioLabs
 PPD Laboratories
 WuXi Advanced Therapies
 AnaBioTec
 Intertek Pharmaceutical Services
 Lonza
 Porton Bio

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Roots Analysis社の分野での最新刊レポート

最新刊レポートはありません。

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

Roots Analysisは2013年設立の医薬品・医療機器が専門の調査会社です。医薬品の製造委託や創薬のデジタル化など、最新の医薬業界の分析を行っています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Roots Analysis社の分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

Roots Analysis社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?